04/07/2021

New Indication Approved for Pfizer Biosimilar ZIRABEV

On behalf of Pfizer, it is our pleasure to inform you that on February 9th, 2021, Pfizer received FDA approval for the inclusion of epithelial ovarian, fallopian tube, and primary peritoneal cancer to the indications of ZIRABEV® (bevacizumab-bvzr).

There were also updates to align the ZIRABEV USPI with that of the reference product, AVASTIN incorporating revisions related to wound healing and the addition of adverse drug reactions, arterial aneurysms, dissections, and rupture to the Post Marketing Experience section.

ZIRABEV is currently the only bevacizumab biosimilar to be granted approval for epithelial ovarian, fallopian tube, and primary peritoneal cancer indications.

Please review the ZIRABEV Full Prescribing Information, including BOXED WARNINGS, for detailed information.

ZIRABEV® is a registered trademark of Pfizer Inc. 

ϮAvastin® is a registered trademark of Genentech, Inc.